© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#Biktarvy
FDA Approves Gilead’s Single-Tablet HIV Regimen Biktarvy
Biktarvy (bictegravir + tenofovir alafenamide + emtricitabine) 101
Chart of Approved and Experimental HIV Medications

Biktarvy Maintains High Efficacy for Three Years in Clinical Trials

The integrase inhibitor–based HIV regimen was compared with dolutegravir-based regimens.

Switching to New Tenofovir Linked to Rise in BMI and Cardiovascular Risk

This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.

Who Gains Weight After Switching to Integrase Inhibitors?

Researchers at George Washington University take a look.

Switching Back to Older Tenofovir Improves Lipid Levels

The newer tenofovir formulation can raise cholesterol and triglyceride levels, but these changes are reversible.

The International AIDS Society Conference’s Most Vital Findings

A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.

Only Subnormal Kidney Function May Get Boost From Switch to New Tenofovir

Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.

Biktarvy Suppresses HIV Well in Women and Those With Drug Resistance

Currently, Gilead Sciences’ HIV regimen is not approved to treat drug-resistant virus.

CROI 2019: So Much More Than an HIV Cure Extravaganza

The Conference on Retroviruses and Opportunistic Infections in Seattle saw many important studies that are advancing the fight against HIV.

Biktarvy Continues to Suppress HIV Well in Long-Term Follow-Up

This held true even among those with resistance to nucleoside/nucleotide reverse transcriptase inhibitors.

Integrase Inhibitors May Be Tied to Weight Gain

More high-quality evidence is needed to determine how this class of HIV medications may affect weight gain.

Older Tenofovir May Not Be Tied to Fracture Risk After All

Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.

Switching to New Tenofovir Is Tied to Higher LDL Cholesterol

Researchers call for closer cardiovascular monitoring for those switching from the TDF form of the drug to the TAF version.

Gilead’s Biktarvy Is as Effective as Tivicay Plus Descovy

Biktarvy has a lower rate of adverse health events, according to 96-week data.
Biktarvy

Biktarvy Is as Effective at Treating HIV as Triumeq

Gilead Sciences has released 96-week results from an ongoing double-blinded study comparing the two regimens.

Canada Approves Gilead’s Biktarvy for HIV Treatment

The new single-tablet antiretroviral regimen includes the integrase inhibitor bictegravir and is the smallest such tablet on the market.
Gilead’s float in the Seattle LGBT pride parade, June 2017

Is Gilead’s Entire HIV Enterprise Built on a False Promise?

A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.
Advertisement
Treatment News
Features